Literature DB >> 2286463

Fosfomycin trometamol: activity in vitro against urinary tract pathogens.

D Greenwood1.   

Abstract

The spectrum of activity of fosfomycin embraces all the common causes of uncomplicated urinary tract infection. The activity is greatly affected by the conditions of the test. Glucose, phosphates and NaCl all interfere with the activity of the drug, whereas glucose-6-phosphate has a marked potentiating effect against many strains. The activity of fosfomycin is greater at acid than at alkaline pH; inoculum density also has an effect, but this is less marked at acid pH values. Fosfomycin is rapidly bactericidal to susceptible bacteria, causing lysis within 30 min. In contrast, fosmidomycin, which also has a narrower spectrum of activity than fosfomycin, is much more slowly bactericidal. In the form of its trometamol salt, fosfomycin is well absorbed after oral administration, and is excreted in high concentration in the urine. Experiments in an in-vitro model of the treatment of bacterial cystitis suggest that concentrations of fosfomycin achievable in urine after oral administration of high doses of the trometamol salt have a marked suppressive effect on bacterial growth without favouring the emergence of resistant mutants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2286463     DOI: 10.1007/bf01643429

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 2.  An in vitro model of the urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  J Antimicrob Chemother       Date:  1978-03       Impact factor: 5.790

3.  Phosphonomycin. 3. Evaluation in vitro.

Authors:  D Hendlin; B M Frost; E Thiele; H Kropp; M E Valiant; B Pelak; B Weissberger; C Cornin; A K Miller
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

4.  Phosphonomycin. IV. Susceptibility testing method and survey.

Authors:  S B Zimmerman; E O Stapley; H Wallick; R Baldwin
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

5.  The trometamol salt of fosfomycin: microbiological evaluation.

Authors:  D Greenwood; S Coyle; J Andrew
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

6.  In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.

Authors:  H C Neu; T Kamimura
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

7.  Fosfomycin-resistance plasmids determine an intracellular modification of fosfomycin.

Authors:  J León; J M García-Lobo; J Navas; J M Ortiz
Journal:  J Gen Microbiol       Date:  1985-07

8.  Fosfomycin, antimicrobial activity in vitro and in vivo.

Authors:  S Goto
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

9.  Pharmacokinetic profile of fosfomycin trometamol (Monuril).

Authors:  G Segre; E Bianchi; A Cataldi; G Zannini
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

View more
  5 in total

1.  An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

Review 2.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women.

Authors:  G Elhanan; H Tabenkin; R Yahalom; R Raz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Identification of Novel Conjugative Plasmids with Multiple Copies of fosB that Confer High-Level Fosfomycin Resistance to Vancomycin-Resistant Enterococci.

Authors:  Lingyan Sun; Ping Zhang; Tingting Qu; Yan Chen; Xiaoting Hua; Keren Shi; Yunsong Yu
Journal:  Front Microbiol       Date:  2017-08-15       Impact factor: 5.640

5.  Fosmidomycin, an inhibitor of isoprenoid synthesis, induces persistence in Chlamydia by inhibiting peptidoglycan assembly.

Authors:  Jessica A Slade; Mary Brockett; Raghuveer Singh; George W Liechti; Anthony T Maurelli
Journal:  PLoS Pathog       Date:  2019-10-17       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.